Evidence map›Paper›PMID 35978206›Full record

ArticleAnnals of surgical oncology2022

Prognostic Factors and Survival in Gastrointestinal Extrapulmonary Small Cell Carcinoma: A Retrospective Cohort Study.

Mark B Ulanja, Bryce D Beutler, Daniel Antwi-Amoabeng, Samuel Bisilki Governor, Ganiyu A Rahman, Francis Tanam Djankpa, Olatunji B Alese

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Mark B UlanjaChristus Ochsner St. Patrick Hospital, Lake Charles, LA, USA. markulanja@gmail.com.
Bryce D BeutlerDepartment of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Daniel Antwi-AmoabengChristus Ochsner St. Patrick Hospital, Lake Charles, LA, USA.
Samuel Bisilki GovernorWashington University in St Louis, School of Medicine, St Louis, MO, USA.
Ganiyu A RahmanDepartment of Surgery, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana.
Francis Tanam DjankpaDepartment of Physiology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana.
Olatunji B AleseDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
CHRISTUS St. Patrick Hospital · USUniversity of Cape Coast · GHEmory University · USUniversity of Southern California · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastrointestinal extrapulmonary small cell carcinoma (GI EPSCCa) is a rare, aggressive neuroendocrine tumor. Factors affecting survival, including the prognostic significance of primary tumor site, remain under investigation.

methodsData from the surveillance, epidemiology, and end results (SEER) program were extracted to identify patients diagnosed with GI EPSCCa between 2000 and 2018. Cox proportional hazard models were used to assess prognostic factors based on primary tumor site.

resultsA total of 1687 patients were included in the survival analysis. The distribution of the primary tumor location was as follows: 31.5% colorectum (CRC), 22.1% esophageal, 20.6% pancreatic, 13.3% hepatobiliary (HB), 10.6% stomach, and 1.8% small intestine (SI). Esophagogastric and SI EPSCCa were more common among Black individuals, whereas CRC, HB, and pancreatic EPSCCa were more common among White patients (p = 0.012). There were no racial differences in OS for GI EPSCCa. HB EPSCCa was associated with inferior OS compared with esophageal tumors (adjusted hazard ratio [aHR] 1.21, 95% confidence interval [CI] 1.00-1.46; p = 0.048), and SI EPSCCa was associated with prolonged survival compared with esophageal EPSCCa (aHR 0.76, 95% CI 0.48-1.20; p = 0.237) but did not reach statistical significance. Surgical intervention and a treatment period after 2006 were associated with superior OS.

conclusionsThe prognosis for GI ESPCCa varies based on site. Chemotherapy, radiation, and surgical resection are associated with improved outcomes; however, the prognosis for patients with EPSCCa remains dismal. Prospective studies are needed to guide therapy for this aggressive tumor.

Indexed as

Carcinoma, Small CellHumansPrognosisRetrospective StudiesSEER ProgramSurvival Analysis

Identifiers

PMID35978206
OpenAlexW4292121719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.